559 related articles for article (PubMed ID: 27631893)
1. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
[TBL] [Abstract][Full Text] [Related]
2. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
[TBL] [Abstract][Full Text] [Related]
4. Rapid generation of CMV pp65-specific T cells for immunotherapy.
Bao L; Sun Q; Lucas KG
J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
[TBL] [Abstract][Full Text] [Related]
5. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
[TBL] [Abstract][Full Text] [Related]
6. Influence of HIV infection on cytomegalovirus-specific immunity: T-cell responses to pp65 and IE1 before and after HAART may reflect altered cytomegalovirus biology.
Scherrenburg J; Schellens IM; van Baarle D
Antivir Ther; 2011; 16(4):565-75. PubMed ID: 21685544
[TBL] [Abstract][Full Text] [Related]
7. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
8. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
9. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
10. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
[TBL] [Abstract][Full Text] [Related]
11. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
12. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
14. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.
Meij P; Jedema I; Zandvliet ML; van der Heiden PL; van de Meent M; van Egmond HM; van Liempt E; Hoogstraten C; Kruithof S; Veld S; Marijt EW; von dem Borne PA; Lankester AC; Halkes CJ; Falkenburg JH
J Immunother; 2012 Oct; 35(8):621-8. PubMed ID: 22996368
[TBL] [Abstract][Full Text] [Related]
16. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
[TBL] [Abstract][Full Text] [Related]
17. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.
Gibson L; Piccinini G; Lilleri D; Revello MG; Wang Z; Markel S; Diamond DJ; Luzuriaga K
J Immunol; 2004 Feb; 172(4):2256-64. PubMed ID: 14764694
[TBL] [Abstract][Full Text] [Related]
18. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
19. Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation.
Flinsenberg TW; Spel L; Jansen M; Koning D; de Haar C; Plantinga M; Scholman R; van Loenen MM; Nierkens S; Boon L; van Baarle D; Heemskerk MH; Boelens JJ; Boes M
J Virol; 2015 Jan; 89(2):1058-69. PubMed ID: 25378489
[TBL] [Abstract][Full Text] [Related]
20. Human bone marrow as a source to generate CMV-specific CD4+ T cells with multifunctional capacity.
Na IK; Letsch A; Guerreiro M; Bauer S; Noack I; Geginat J; Reinke P; Loesch M; Kienapfel H; Thiel E; Volk HD; Scheibenbogen C
J Immunother; 2009; 32(9):907-13. PubMed ID: 19816191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
